首页> Multiple sclerosis (Houndmills, Basingstoke, England)> A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.

A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.

导出 OA

翻译打印收藏纠错

第一作者： Edward,Fox

第一单位： Central Texas Neurology Consultants, Round Rock, TX, USA.

作者： Edward,Fox ^[1] ; Amy E,Lovett-Racke ^[2] ; Matthew,Gormley ^[2] ; Yue,Liu ^[2] ; Maria,Petracca ^[3] ; Sirio,Cocozza ^[4] ; Richard,Shubin ^[5] ; Sibyl,Wray ^[6] ; Michael S,Weiss ^[7] ; Jenna A,Bosco ^[7] ; Sean A,Power ^[7] ; Koby,Mok ^[7] ; Matilde,Inglese ^[8]

作者单位： Central Texas Neurology Consultants, Round Rock, TX, USA. ^[1] Department of Microbial Infection and Immunity, The Ohio State University Wexner Medical Center, Columbus, OH, USA. ^[2] Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ^[3] Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA/Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy. ^[4] SC3 Research Group, Inc., Pasadena, CA, USA. ^[5] Hope Neurology Multiple Sclerosis Center, Knoxville, TN, USA. ^[6] TG Therapeutics, Inc., New York, NY, USA. ^[7] Medical Center, Department of Neurology, Radiology and Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ^[8]

关键词 TG-1101 Ublituximab gadolinium-enhancing lesions magnetic resonance imaging multiple sclerosis relapse

医学主题词抗体, 单克隆(Antibodies, Monoclonal);抗原, CD20(Antigens, CD20);人类(Humans);磁共振成像(Magnetic Resonance Imaging);多发性硬化(Multiple Sclerosis);多发性硬化, 复发缓解性(Multiple Sclerosis, Relapsing-Remitting);复发(Recurrence)

DOI 10.1177/1352458520918375

PMID 32351164

发布时间 2021-09-24

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交